Interferons, signal transduction pathways, and the central nervous system

Journal of Interferon and Cytokine Research

Volumn 34, Issue 8, 2014, Pages 559-576

  Nallar, Shreeram C ^a   Kalvakolanu, Dhan V ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; STAT1 PROTEIN; TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; AICARDI GOUTIERES SYNDROME; ANTIGEN PRESENTATION; AUTOIMMUNITY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE; CELL STRESS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; DNA DAMAGE; ENZYME ACTIVITY; GENE EXPRESSION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LEIGH DISEASE; MOLECULAR PATHOLOGY; NERVE CELL; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SPINAL MUSCULAR ATROPHY; TRANSCRIPTION INITIATION; VIRUS INFECTION; VIRUS PATHOGENESIS; ANIMAL; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANIMALS; AUTOIMMUNE DISEASES; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DNA DAMAGE; HUMANS; INTERFERONS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84905368726     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0021     Document Type: Review

References (198)

1. Adachi Y, Yamamoto K, Okada T, Yoshida H, Harada A, Mori K. 2008. ATF6 is a transcription factor specializing in the regulation of quality control proteins in the endoplasmic re-ticulum. Cell Struct Funct 33(1):75-89.
2. Agapitos E, Pavlopoulos PM, Patsouris E, Davaris P. 1997. Subacute necrotizing encephalomyelopathy (Leigh's disease): a clinicopathologic study of ten cases. Gen Diagn Pathol 142(5-6):335-341.
3. Akira S, Kishimoto T. 1997. NF-IL6 and NF-kappa B in cytokine gene regulation. Adv Immunol 65:1-46.
4. Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A, Yakirevich E, Konforty D, Alroy I, Zhao X, Reddy SP, Resnick MB, Kalvakolanu DV. 2006. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 25(54):7138-7147.
5. Alexander WS, Hilton DJ. 2004. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22:503-529.
6. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98(5):597-608.
7. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE. 2004. The V proteins of para-myxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 101(49):17264-17269.
8. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV. 2000. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem 275(43):33416-33426.
9. Bach EA, Aguet M, Schreiber RD. 1997. The IFN-g receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563-591.
10. Baron-Delage S, Abadie A, Echaniz-Laguna A, Melki J, Beretta L. 2000. Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med 6(11):957-968.
11. Bialik S, Kimchi A. 2006. The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochem 75: 189-210.
12. Bluyssen AR, Durbin JE, Levy DE. 1996. ISGF3 gamma p48, a specificity switch for interferon activated transcription factors. Cytokine Growth Factor Rev 7(1):11-17.
13. Bocket L, Delforge F, Wattre P, Lemaitre JF, Hober D, Dewilde A. 1992. [Value of interferon alpha determination in the diagnosis of meningoencephalitis presumed to be of viral origin]. Rev Med Interne 13(1):27-31.
14. Boehm U, Klamp T, Groot M, Howard JC. 1997. Cellular responses to interferon-g. Annu Rev Immunol 15:749-795.
15. Bogdan C. 2000. The function of type I interferons in antimicrobial immunity. Curr Opin Immunol 12(4):419-424.
16. Boisson-Dupuis S, Kong XF, Okada S, Cypowyj S, Puel A, Abel L, Casanova JL. 2012. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr Opin Immunol 24(4): 364-378.
17. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12):975-990.
18. Brault ME, Lauzon C, Autexier C. 2013. Dyskeratosis con-genita mutations in dyskerin SUMOylation consensus sites lead to impaired telomerase RNA accumulation and telomere defects. Hum Mol Genet 22(17):3498-3507.
19. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E, Reaume AG, Scott RW, Cleveland DW. 1998. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281(5384):1851-1854.
20. Brzozka K, Finke S, Conzelmann KK. 2006. Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J Virol 80(6): 2675-2683.
21. Campbell IL. 1998. Transgenic mice and cytokine actions in the brain: bridging the gap between structural and functional neuropathology. Brain Res Brain Res Rev 26(2-3):327-336.
22. Campbell IL, Krucker T, Steffensen S, Akwa Y, Powell HC, Lane T, Carr DJ, Gold LH, Henriksen SJ, Siggins GR. 1999. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res 835(1):46-61.
23. Cardinaux JR, Allaman I, Magistretti PJ. 2000. Pro-inflammatory cytokines induce the transcription factors C/EBPbeta and C/EBPdelta in astrocytes. Glia 29(1):91-97.
24. Cardinaux JR, Magistretti PJ. 1996. Vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, and noradrenaline induce the transcription factors CCAAT/enhancer binding protein (C/EBP)-beta and C/EBP delta in mouse cortical astrocytes: involvement in cAMP-regulated glycogen metabolism. J Neurosci 16(3):919-929.
25. Chandra D, Singh KK. 2011. Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta 1807(6):620-625.
26. Chen J, Baig E, Fish EN. 2004. Diversity and relatedness among the type I interferons. J Interferon Cytokine Res 24(12): 687-698.
27. Chen M, Rockel T, Steinweger G, Hemmerich P, Risch J, von Mikecz A. 2002. Subcellular recruitment of fibrillarin to nucleoplasmic proteasomes: implications for processing of a nucleolar autoantigen. Mol Biol Cell 13(10):3576-3587.
28. Chen Y, Lu H, Liu Q, Huang G, Lim CP, Zhang L, Hao A, Cao X. 2012. Function of GRIM-19, a mitochondrial respiratory chain complex I protein, in innate immunity. J Biol Chem 287(32):27227-27235.
29. Cohen O, Feinstein E, Kimchi A. 1997. DAP-kinase is a Ca 2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 16(5):998-1008.
30. Colangelo AM, Johnson PF, Mocchetti I. 1998. beta-adrenergic receptor-induced activation of nerve growth factor gene transcription in rat cerebral cortex involves CCAAT/enhancer-binding protein delta. Proc Natl Acad Sci USA 95(18): 10920-10925.
31. Compston A, Zajicek J, Sussman J, Webb A, Hall G, Muir D, Shaw C, Wood A, Scolding N. 1997. Glial lineages and myelination in the central nervous system. J Anat 190 (Pt 2): 161-200.
32. Cook-Easterwood J, Middaugh LD, Griffin WC 3rd, Khan I, Tyor WR. 2007. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp Neurol 205(2):506-512.
33. Corbin JG, Kelly D, Rath EM, Baerwald KD, Suzuki K, Popko B. 1996. Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol Cell Neurosci 7(5):354-370.
34. Croniger C, Trus M, Lysek-Stupp K, Cohen H, Liu Y, Darlington GJ, Poli V, Hanson RW, Reshef L. 1997. Role of the isoforms of CCAAT/enhancer-binding protein in the initiation of phosphoenolpyruvate carboxykinase (GTP) gene transcription at birth. J Biol Chem 272(42):26306-26312.
35. Crow YJ. 2011. Type I interferonopathies: a novel set of inborn errors of immunity. Ann NY Acad Sci 1238:91-98.
36. Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, Griffith E, Ali M, Semple C, Aicardi J, Babul-Hirji R, Baumann C, Baxter P, Bertini E, Chandler KE, Chitayat D, Cau D, Dery C, Fazzi E, Goizet C, King MD, Klepper J, Lacombe D, Lanzi G, Lyall H, Martinez-Frias ML, Mathieu M, McKeown C, Monier A, Oade Y, Quarrell OW, Rittey CD, Rogers RC, Sanchis A, Stephenson JB, Tacke U, Till M, Tolmie JL, Tomlin P, Voit T, Weschke B, Woods CG, Lebon P, Bonthron DT, Ponting CP, Jackson AP. 2006. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet 38(8):910-916.
37. Darlington GJ, Ross SE, MacDougald OA. 1998. The role of C/EBP genes in adipocyte differentiation. J Biol Chem 273(46):30057-30060.
38. Dedoni S, Olianas MC, Ingianni A, Onali P. 2012. Type I interferons impair BDNF-induced cell signaling and neurotrophic activity in differentiated human SH-SY5Y neuroblastoma cells and mouse primary cortical neurons. J Neurochem 122(1): 58-71.
39. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. 1995. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 9(1):15-30.
40. Delarasse C, Daubas P, Mars LT, Vizler C, Litzenburger T, Iglesias A, Bauer J, Della Gaspera B, Schubart A, Decker L, Dimitri D, Roussel G, Dierich A, Amor S, Dautigny A, Li-blau R, Pham-Dinh D. 2003. Myelin/oligodendrocyte glyco-protein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest 112(4):544-553.
41. Delhaye S, Paul S, Blakqori G, Minet M, Weber F, Staeheli P, Michiels T. 2006. Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci USA 103(20):7835-7840.
42. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR. 2001. Functional classification of interferon-stimulated genes identified using micro-arrays. J Leukoc Biol 69(6):912-920.
43. de Weerd NA, Samarajiwa SA, Hertzog PJ. 2007. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282(28):20053-20057.
44. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. 2004. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 279(31):32269-32274.
45. Dussaix E, Lebon P, Ponsot G, Huault G, Tardieu M. 1985. Intrathecal synthesis of different alpha-interferons in patients with various neurological diseases. Acta Neurol Scand 71(6):504-509.
46. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A; Investigators of the 16-year Long-Term Follow-Up Study. 2010. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 81(8):907-912.
47. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG. 1996. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156(1):5-7.
48. Ferrantini M, Capone I, Belardelli F. 2007. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89(6-7):884-893.
49. Franchi L, Warner N, Viani K, Nunez G. 2009. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 227(1):106-128.
50. Fujita N, Kemper A, Dupree J, Nakayasu H, Bartsch U, Schachner M, Maeda N, Suzuki K, Popko B. 1998. The cy-toplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination. J Neurosci 18(6):1970-1978.
51. Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA, De Weerd N, Roisman LC, Rossjohn J, Robertson SA, Schjenken JE, Parker B, Gargett CE, Nguyen HP, Carr DJ, Hansbro PM, Hertzog PJ. 2013. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 339(6123):1088-1092.
52. Gade P, Ramachandran G, Maachani UB, Rizzo MA, Okada T, Prywes R, Cross AS, Mori K, Kalvakolanu DV. 2012. An IFN-gamma-stimulated ATF6-C/EBP-beta- signaling pathway critical for the expression of Death Associated Protein Kinase 1 and induction of autophagy. Proc Natl Acad Sci USA 109(26):10316-10321.
53. Gade P, Roy SK, Li H, Nallar SC, Kalvakolanu DV. 2008. Critical role for transcription factor C/EBP-beta in regulating the expression of death-associated protein kinase 1. Mol Cell Biol 28(8):2528-2548.
54. George CX, Wagner MV, Samuel CE. 2005. Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing. J Biol Chem 280(15):15020-15028.
55. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD. 2001. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci USA 98(12):6680-6685.
56. Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V; Year Long-Term Follow-up Study I. 2011. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One 6(11):e22444.
57. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. 2012. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 78(17):1315-1322.
58. Gozuacik D, Kimchi A. 2006. DAPk protein family and cancer. Autophagy 2(2):74-79.
59. Greenlund AC, Morales MO, Viviano BL, Yan H, Krolewski J, Schreiber RD. 1995. Stat recruitment by tyrosine-phosphor-ylated cytokine receptors: an ordered reversible affinity-driven process. Immunity 2(6):677-687.
60. Guiducci C, Coffman RL, Barrat FJ. 2009. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 265(1):43-57.
61. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. 2004. Characterization of the type I interferon locus and identification of novel genes. Genomics 84(2):331-345.
62. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. 2001. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 97(2):473-482.
63. Harle P, Sainz B Jr., Carr DJ, Halford WP. 2002. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/beta. Virology 293(2):295-304.
64. Hawkins BT, Davis TP. 2005. The blood-brain barrier/neuro-vascular unit in health and disease. Pharmacol Rev 57(2): 173-185.
65. Herrera-Esparza R, Kruse L, von Essen M, Campos L, Barbosa O, Bollain JJ, Badillo I, Avalos-Diaz E. 2002. U3 snoRNP associates with fibrillarin a component of the scleroderma clumpy nucleolar domain. Arch Dermatol Res 294(7): 310-317.
66. Hess B, Saftig P, Hartmann D, Coenen R, Lullmann-Rauch R, Goebel HH, Evers M, von Figura K, D'Hooge R, Nagels G, De Deyn P, Peters C, Gieselmann V. 1996. Phenotype of arylsulfatase A-deficient mice: relationship to human meta-chromatic leukodystrophy. Proc Natl Acad Sci USA 93(25):14821-14826.
67. Hideyama T, Yamashita T, Aizawa H, Tsuji S, Kakita A, Ta-kahashi H, Kwak S. 2012. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis 45(3):1121-1128.
68. Higuchi M, Maas S, Single FN, Hartner J, Rozov A, Burnashev N, Feldmeyer D, Sprengel R, Seeburg PH. 2000. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature 406(6791):78-81.
69. Hofer MJ, Campbell IL. 2013. Type I interferon in neurological disease-the devil from within. Cytokine Growth Factor Rev 24(3):257-267.
70. Hofer MJ, Li W, Lim SL, Campbell IL. 2010. The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9. J Neurosci 30(3):1149-1157.
71. Hofmann ER, Nallar SC, Lin L, D'Cunha J, Lindner DJ, Weihua X, Kalvakolanu DV. 2010. Identification and characterization of GRIM-1, a cell-death-associated gene product. J Cell Sci 123(Pt 16):2781-2791.
72. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, Anderson VL, Darnell DN, Welch PA, Kuhns DB, Frucht DM, Malech HL, Gallin JI, Kobayashi SD, Whitney AR, Voyich JM, Musser JM, Woellner C, Schaffer AA, Puck JM, Grimbacher B. 2007. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 357(16):1608-1619.
73. Hovelmeyer N, Hao Z, Kranidioti K, Kassiotis G, Buch T, Frommer F, von Hoch L, Kramer D, Minichiello L, Kollias G, Lassmann H, Waisman A. 2005. Apoptosis of oligoden-drocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J Immunol 175(9):5875-5884.
74. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H. 2000. A mouse model for spinal muscular atrophy. Nat Genet 24(1):66-70.
75. Huang G, Chen Y, Lu H, Cao X. 2007. Coupling mitochon-drial respiratory chain to cell death: an essential role of mitochondrial complex I in the interferon-beta and retinoic acid-induced cancer cell death. Cell Death Differ 14(2): 327-337.
76. Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K, Lufei C, Zeng Q, Cao X. 2004. GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochon-drial complex I. Mol Cell Biol 24(19):8447-8456.
77. Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T, Yoneyama M, Fujita T, Taya C, Yonekawa H, Koike S. 2005. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 79(7):4460-4469.
78. Iivanainen M, Laaksonen R, Niemi ML, Farkkila M, Bergstrom L, Mattson K, Niiranen A, Cantell K. 1985. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol Scand 72(5):475-480.
79. Inbal B, Bialik S, Sabanay I, Shani G, Kimchi A. 2002. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol 157(3):455-468.
80. Jacobs EC, Pribyl TM, Feng JM, Kampf K, Spreur V, Cam-pagnoni C, Colwell CS, Reyes SD, Martin M, Handley V, Hiltner TD, Readhead C, Jacobs RE, Messing A, Fisher RS, Campagnoni AT. 2005. Region-specific myelin pathology in mice lacking the golli products of the myelin basic protein gene. J Neurosci 25(30):7004-7013.
81. Jouanguy E, Zhang SY, Chapgier A, Sancho-Shimizu V, Puel A, Picard C, Boisson-Dupuis S, Abel L, Casanova JL. 2007. Human primary immunodeficiencies of type I interferons. Biochimie 89(6-7):878-883.
82. Kalakonda S, Nallar SC, Jaber S, Keay SK, Rorke E, Muni-venkatappa R, Lindner DJ, Fiskum GM, Kalvakolanu DV. 2013. Monoallelic loss of tumor suppressor GRIM-19 promotes tumorigenesis in mice. Proc Natl Acad Sci USA 110(45):E4213-E4222.
83. Kallfass C, Ackerman A, Lienenklaus S, Weiss S, Heimrich B, Staeheli P. 2012. Visualizing production of beta interferon by astrocytes and microglia in brain of La Crosse virus-infected mice. J Virol 86(20):11223-11230.
84. Kalvakolanu DV. 2003. Alternate interferon signaling pathways. Pharmacol Ther 100(1):1-29.
85. Kalvakolanu DV. 2004. The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev 15(2-3):169-194.
86. Kalvakolanu DV, Choi K, Borden EC. 2001. Interferons and hematopoeitic cytokines. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia: W.B. Saunders Company, pp 503-534.
87. Kalvakolanu DV, Nallar SC, Kalakonda S. 2010. Cytokine-induced tumor suppressors: a GRIM story. Cytokine 52(1-2): 128-142.
88. Kapil P, Butchi NB, Stohlman SA, Bergmann CC. 2012. Oli-godendroglia are limited in type I interferon induction and responsiveness in vivo. Glia 60(10):1555-1566.
89. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, McCoy B, Bogdan C, Decker T, Brem G, Pfeffer K, Muller M. 2000. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13(4):549-560.
90. Kaur S, Sassano A, Majchrzak-Kita B, Baker DP, Su B, Fish EN, Platanias LC. 2012. Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proc Natl Acad Sci USA 109(20):7723-7728.
91. Kawai T, Akira S. 2009. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21(4):317-337.
92. Klugmann M, Schwab MH, Puhlhofer A, Schneider A, Zimmermann F, Griffiths IR, Nave KA. 1997. Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18(1):59-70.
93. Knight SW, Heiss NS, Vulliamy TJ, Aalfs CM, McMahon C, Richmond P, Jones A, Hennekam RC, Poustka A, Mason PJ, Dokal I. 1999a. Unexplained aplastic anaemia, immunodeficiency, and cerebellar hypoplasia (Hoyeraal-Hreidarsson syndrome) due to mutations in the dyskeratosis congenita gene, DKC1. Br J Haematol 107(2):335-339.
94. Knight SW, Heiss NS, Vulliamy TJ, Greschner S, Stavrides G, Pai GS, Lestringant G, Varma N, Mason PJ, Dokal I, Poustka A. 1999b. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 65(1):50-58.
95. Knisz J, Banks A, McKeag L, Metcalfe DD, Rothman PB, Brown JM. 2009. Loss of SOCS7 in mice results in severe cutaneous disease and increased mast cell activation. Clin Immunol 132(2):277-284.
96. Komar AA, Hatzoglou M. 2011. Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle 10(2):229-240.
97. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
98. Krakowski M, Owens T. 1996. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 26(7):1641-1646.
99. Krebs DL, Metcalf D, Merson TD, Voss AK, Thomas T, Zhang JG, Rakar S, O'Bryan MK, Willson TA, Viney EM, Mielke LA, Nicola NA, Hilton DJ, Alexander WS. 2004. Development of hydrocephalus in mice lacking SOCS7. Proc Natl Acad Sci USA 101(43):15446-15451.
100. Kruse SE, Watt WC, Marcinek DJ, Kapur RP, Schenkman KA, Palmiter RD. 2008. Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell Metab 7(4):312-320.
101. LaFerla FM, Sugarman MC, Lane TE, Leissring MA. 2000. Regional hypomyelination and dysplasia in transgenic mice with astrocyte-directed expression of interferon-gamma. J Mol Neurosci 15(1):45-59.
102. Lee E, Chanamara S, Pleasure D, Soulika AM. 2012. IFN-gamma signaling in the central nervous system controls the course of experimental autoimmune encephalomyelitis independently of the localization and composition of inflammatory foci. J Neuroinflammation 9:7.
103. Lees JR, Golumbek PT, Sim J, Dorsey D, Russell JH. 2008. Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med 205(11):2633-2642.
104. Lekstrom-Himes J, Xanthopoulos KG. 1998. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem 273(44):28545-28548.
105. Lenaz G, Genova ML. 2010. Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject. Antioxid Redox Signal 12(8):961-1008.
106. Leung S, Qureshi SA, Kerr IM, Darnell JE Jr., Stark GR. 1995. Role of STAT2 in the alpha interferon signaling pathway. Mol Cell Biol 15(3):1312-1317.
107. Li C, Tropak MB, Gerlai R, Clapoff S, Abramow-Newerly W, Trapp B, Peterson A, Roder J. 1994. Myelination in the absence of myelin-associated glycoprotein. Nature 369(6483): 747-750.
108. Li Y, Sassano A, Majchrzak B, Deb DK, Levy DE, Gaestel M, Nebreda AR, Fish EN, Platanias LC. 2004. Role of p38alpha Map kinase in type I interferon signaling. J Biol Chem 279(2):970-979.
109. Liedtke W, Edelmann W, Bieri PL, Chiu FC, Cowan NJ, Ku-cherlapati R, Raine CS. 1996. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 17(4):607-615.
110. Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, Toubiana J, Itan Y, Audry M, Nitschke P, Masson C, Toth B, Flatot J, Migaud M, Chrabieh M, Kochetkov T, Bolze A, Borghesi A, Toulon A, Hiller J, Eyerich S, Eyerich K, Gulacsy V, Chernyshova L, Chernyshov V, Bondarenko A, Grimaldo RM, Blancas-Galicia L, Beas IM, Roesler J, Magdorf K, Engelhard D, Thumerelle C, Burgel PR, Hoernes M, Drexel B, Seger R, Kusuma T, Jansson AF, Sawalle-Belohradsky J, Belohradsky B, Jouanguy E, Bustamante J, Bue M, Karin N, Wildbaum G, Bodemer C, Lortholary O, Fischer A, Blanche S, Al-Muhsen S, Reichenbach J, Kobayashi M, Rosales FE, Lozano CT, Kilic SS, Oleastro M, Etzioni A, Traidl-Hoffmann C, Renner ED, Abel L, Picard C, Marodi L, Boisson-Dupuis S, Puel A, Casanova JL. 2011. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208(8):1635-1648.
111. Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW, Smith KD. 1997. A mouse model for X-linked adreno-leukodystrophy. Proc Natl Acad Sci USA 94(17):9366-9371.
112. Luzi P, Rafi MA, Zaka M, Curtis M, Vanier MT, Wenger DA. 2001. Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leu-kodystrophy (Krabbe disease). Mol Genet Metab 73(3): 211-223.
113. Marine JC, Topham DJ, McKay C, Wang D, Parganas E, Stravopodis D, Yoshimura A, Ihle JN. 1999. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98(5):609-616.
114. Masliah E, Roberts ES, Langford D, Everall I, Crews L, Adame A, Rockenstein E, Fox HS. 2004. Patterns of gene dysregu-lation in the frontal cortex of patients with HIV encephalitis. J Neuroimmunol 157(1-2):163-175.
115. Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, Campbell GA, Matalon K, Ceci JD, Tyring SK, Nehls M, Surendran S, Wei J, Ezell EL, Szucs S. 2000. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. J Gene Med 2(3):165-175.
116. Mattson K, Niiranen A, Iivanainen M, Farkkila M, Bergstrom L, Holsti LR, Kauppinen HL, Cantell K. 1983. Neurotoxicity of interferon. Cancer Treat Rep 67(10):958-61.
117. McBride KM, Reich NC. 2003. The ins and outs of STAT1 nuclear transport. Sci STKE 2003(195):RE13.
118. McCall MA, Gregg RG, Behringer RR, Brenner M, Delaney CL, Galbreath EJ, Zhang CL, Pearce RA, Chiu SY, Messing A. 1996. Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology. Proc Natl Acad Sci USA 93(13):6361-6366.
119. McGavern DB, Kang SS. 2011. Illuminating viral infections in the nervous system. Nat Rev Immunol 11(5):318-329.
120. Mehrabian Z, Chandrasekaran K, Kalakonda S, Kristian T, Fiskum G, Kalvakolanu DV. 2007. The IFN-beta and retinoic acid-induced cell death regulator GRIM-19 is upregulated during focal cerebral ischemia. J Interferon Cytokine Res 27(5):383-392.
121. Menichella DM, Goodenough DA, Sirkowski E, Scherer SS, Paul DL. 2003. Connexins are critical for normal myelination in the CNS. J Neurosci 23(13):5963-5973.
122. Mogensen TH. 2009. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22(2):240-273, Table of Contents.
123. Montag D, Giese KP, Bartsch U, Martini R, Lang Y, Bluthmann H, Karthigasan J, Kirschner DA, Wintergerst ES, Nave KA, et al. 1994. Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron 13(1):229-246.
124. Morita M, Stamp G, Robins P, Dulic A, Rosewell I, Hrivnak G, Daly G, Lindahl T, Barnes DE. 2004. Gene-targeted mice lacking the Trex1 (DNase III) 3¢/5¢ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 24(15):6719-6727.
125. Muller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Sil-vennoinen O, Harpur AG, Barbieri G, Witthuhn BA, Schindler C, et al. 1993a. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and-gamma signal transduction. Nature 366(6451):129-135.
126. Muller M, Laxton C, Briscoe J, Schindler C, Improta T, Darnell JE Jr., Stark GR, Kerr IM. 1993b. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and-gamma signal transduc-tion pathways. EMBO J 12(11):4221-4228.
127. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264(5167): 1918-1921.
128. Naka T, Matsumoto T, Narazaki M, Fujimoto M, Morita Y, Ohsawa Y, Saito H, Nagasawa T, Uchiyama Y, Kishimoto T. 1998. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA 95(26):15577-15582.
129. Nallar SC, Kalakonda S, Lindner DJ, Lorenz RR, Lamarre E, Weihua X, Kalvakolanu DV. 2013. Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis. J Biol Chem 288(11):7930-7941.
130. Nallar SC, Lin L, Srivastava V, Gade P, Hofmann ER, Ahmed H, Reddy SP, Kalvakolanu DV. 2011. GRIM-1, a novel growth suppressor, inhibits rRNA maturation by suppressing small nucleolar RNAs. PLoS One 6(9):e24082.
131. Nelles E, Butzler C, Jung D, Temme A, Gabriel HD, Dahl U, Traub O, Stumpel F, Jungermann K, Zielasek J, Toyka KV, Dermietzel R, Willecke K. 1996. Defective propagation of signals generated by sympathetic nerve stimulation in the liver of connexin32-deficient mice. Proc Natl Acad Sci USA 93(18):9565-9570.
132. Nikoskelainen EK, Marttila RJ, Huoponen K, Juvonen V, Lamminen T, Sonninen P, Savontaus ML. 1995. Leber's "plus": neurological abnormalities in patients with Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 59(2):160-164.
133. Pagenstecher A, Lassmann S, Carson MJ, Kincaid CL, Stalder AK, Campbell IL. 2000. Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic en-cephalomyelitis. J Immunol 164(9):4481-4492.
134. Pashenkov M, Huang YM, Kostulas V, Haglund M, Soderstrom M, Link H. 2001. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 124(Pt 3):480-492.
135. Pecina P, Capkova M, Chowdhury SK, Drahota Z, Dubot A, Vojtiskova A, Hansikova H, Houst'kova H, Zeman J, God-inot C, Houstek J. 2003. Functional alteration of cytochrome c oxidase by SURF1 mutations in Leigh syndrome. Biochim Biophys Acta 1639(1):53-63.
136. Pekny M, Leveen P, Pekna M, Eliasson C, Berthold CH, Westermark B, Betsholtz C. 1995. Mice lacking glial fi-brillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. EMBO J 14(8):1590-1598.
137. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. 2006. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1(3):223-236.
138. Pestka S, Krause CD, Walter MR. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8-32.
139. Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH. 1997. STAT3 as an adapter to couple phosphatidylino-sitol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 276(5317):1418-1420.
140. Piruat JI, Pintado CO, Ortega-Saenz P, Roche M, Lopez-Barneo J. 2004. The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia. Mol Cell Biol 24(24):10933-10940.
141. Platanias LC. 2005. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375-386.
142. Poli V. 1998. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem 273(45):29279-29282.
143. Prinz M, Knobeloch KP. 2012. Type I interferons as ambiguous modulators of chronic inflammation in the central nervous system. Front Immunol 3:67.
144. Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR. 2001. Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci USA 98(12):6674-6679.
145. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH Jr., Scott RW, Snider WD. 1996. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 13(1):43-47.
146. Reyes-Vazquez C, Prieto-Gomez B, Dafny N. 2012. Interferon modulates central nervous system function. Brain Res 1442:76-89.
147. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, Ali M, Gornall H, Couthard LR, Aeby A, Attard-Montalto SP, Bertini E, Bodemer C, Brockmann K, Brueton LA, Corry PC, Desguerre I, Fazzi E, Cazorla AG, Gener B, Hamel BC, Heiberg A, Hunter M, van der Knaap MS, Kumar R, Lagae L, Landrieu PG, Lourenco CM, Marom D, McDermott MF, van der Merwe W, Orcesi S, Prendiville JS, Rasmussen M, Shalev SA, Soler DM, Shinawi M, Spiegel R, Tan TY, Vanderver A, Wakeling EL, Wassmer E, Whittaker E, Lebon P, Stetson DB, Bonthron DT, Crow YJ. 2009. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 41(7):829-832.
148. Rieder M, Brzozka K, Pfaller CK, Cox JH, Stitz L, Conzelmann KK. 2011. Genetic dissection of interferon-antagonistic functions of rabies virus phosphoprotein: inhibition of interferon regulatory factor 3 activation is important for patho-genicity. J Virol 85(2):842-852.
149. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A. 2005. The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci USA 102(27):9577-9582.
150. Ron D, Walter P. 2007. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8(7):519-529.
151. Roy SK, Hu J, Meng Q, Xia Y, Shapiro PS, Reddy SP, Platanias LC, Lindner DJ, Johnson PF, Pritchard C, Pages G, Pouys-segur J, Kalvakolanu DV. 2002. MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc Natl Acad Sci USA 99(12):7945-7950.
152. Roy SK, Wachira SJ, Weihua X, Hu J, Kalvakolanu DV. 2000. CCAAT/Enhancer-binding Protein-b regulates Interferon-induced Transcription through a Novel Element. J Biol Chem 275:12626-12632.
153. Ruggero D. 2013. Translational control in cancer etiology. Cold Spring Harb Perspect Biol 5(2): pii: a012336.
154. Sancho-Shimizu V, Perez de Diego R, Jouanguy E, Zhang SY, Casanova JL. 2011. Inborn errors of anti-viral interferon immunity in humans. Curr Opin Virol 1(6):487-496.
155. Sas AR, Bimonte-Nelson HA, Tyor WR. 2007. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS 21(16):2151-2159.
156. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163-189.
157. Seagroves TN, Krnacik S, Raught B, Gay J, Burgess-Beusse B, Darlington GJ, Rosen JM. 1998. C/EBPbeta, but not C/EB-Palpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev 12(12):1917-1928.
158. Sen GC, Sarkar SN. 2007. The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses. Curr Top Microbiol Immunol 316:233-250.
159. Shan B, Vazquez E, Lewis JA. 1990. Interferon selectively inhibits the expression of mitochondrial genes: a novel pathway for interferon-mediated responses. EMBO J 9(13): 4307-4314.
160. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H. 2012. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308(3):247-256.
161. Shuai K, Stark GR, Kerr IM, Darnell JE Jr. 1993. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 261(5129):1744-1746.
162. Sobol PT, Mossman KL. 2006. ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells. J Virol 80(1):218-225.
163. Sorgeloos F, Kreit M, Hermant P, Lardinois C, Michiels T. 2013. Antiviral type I and type III interferon responses in the central nervous system. Viruses 5(3):834-857.
164. Sporkel O, Uschkureit T, Bussow H, Stoffel W. 2002. Oligo-dendrocytes expressing exclusively the DM20 isoform of the proteolipid protein gene: myelination and development. Glia 37(1):19-30.
165. Stark GR, Darnell JE Jr. 2012. The JAK-STAT pathway at twenty. Immunity 36(4):503-514.
166. Sterneck E, Tessarollo L, Johnson PF. 1997. An essential role for C/EBPbeta in female reproduction. Genes Dev 11(17): 2153-2162.
167. Stetson DB, Ko JS, Heidmann T, Medzhitov R. 2008. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134(4): 587-598.
168. Tamura T, Ozato K. 2002. ICSBP/IRF-8: Its regulatory roles in the development of myeloid cells. J Interferon Cytokine Res 22(1):145-152.
169. Tanaka T, Akira S, Yoshida K, Umemoto M, Yoneda Y, Shirafuji N, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T. 1995. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell 80(2):353-361.
170. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. Irf family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655.
171. Taniguchi T, Takaoka A. 2001. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2(5):378-386.
172. Taubenfeld SM, Milekic MH, Monti B, Alberini CM. 2001. The consolidation of new but not reactivated memory requires hippocampal C/EBPbeta. Nat Neurosci 4(8):813-818.
173. Tran EH, Prince EN, Owens T. 2000. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J Immunol 164(5):2759-2768.
174. Trottier MD, Lyles DS, Reiss CS. 2007. Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol 13(5):433-445.
175. Tu W, Xu X, Peng L, Zhong X, Zhang W, Soundarapandian MM, Balel C, Wang M, Jia N, Lew F, Chan SL, Chen Y, Lu Y. 2010. DAPK1 interaction with NMDA receptor NR2B sub-units mediates brain damage in stroke. Cell 140(2):222-234.
176. Tyor WR, Power C, Gendelman HE, Markham RB. 1993. A model of human immunodeficiency virus encephalitis in scid mice. Proc Natl Acad Sci USA 90(18):8658-8662.
177. Uddin S, Lekmine F, Sharma N, Majchrzak B, Mayer I, Young PR, Bokoch GM, Fish EN, Platanias LC. 2000a. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 275(36):27634-27640.
178. Uddin S, Majchrzak B, Wang PC, Modi S, Khan MK, Fish EN, Platanias LC. 2000b. Interferon-dependent activation of the serine kinase PI 3¢-kinase requires engagement of the IRS pathway but not the Stat pathway. Biochem Biophys Res Commun 270(1):158-162.
179. van den Broek MF, Muller U, Huang S, Zinkernagel RM, Aguet M. 1995. Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev 148:5-18.
180. van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, Arts P, Rosentul DC, Carmichael AJ, Smits-van der Graaf CA, Kullberg BJ, van der Meer JW, Lilic D, Veltman JA, Netea MG. 2011. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365(1):54-61.
181. Veals SA, Santa Maria T, Levy DE. 1993. Two domains of ISGF3 gamma that mediate protein-DNA and protein-protein interactions during transcription factor assembly contribute to DNA-binding specificity. Mol Cell Biol 13(1):196-206.
182. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. 2011. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271.
183. Vidy A, El Bougrini J, Chelbi-Alix MK, Blondel D. 2007. The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1. J Virol 81(8):4255-4263.
184. Wakim LM, Woodward-Davis A, Bevan MJ. 2010. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc Natl Acad Sci USA 107(42):17872-17879.
185. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ 2nd, Nikoskelainen EK. 1988. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242(4884):1427-1430.
186. Wang J, Campbell IL. 2005. Innate STAT1-dependent genomic response of neurons to the antiviral cytokine alpha interferon. J Virol 79(13):8295-8302.
187. Wang J, Pham-Mitchell N, Schindler C, Campbell IL. 2003. Dysregulated Sonic hedgehog signaling and medulloblastoma consequent to IFN-alpha-stimulated STAT2-independent production of IFN-gamma in the brain. J Clin Invest 112(4): 535-543.
188. Wang J, Schreiber RD, Campbell IL. 2002. STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiolog-ical actions of IFN-alpha in the central nervous system. Proc Natl Acad Sci USA 99(25):16209-16214.
189. Wang Q, Khillan J, Gadue P, Nishikura K. 2000. Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science 290(5497):1765-1768.
190. Weihua X, Kolla V, Kalvakolanu DV. 1997. Interferon-g induced transcription of the murine ISGF3g (p48) gene is mediated by novel factors. Proc Natl Acad Sci USA 94:103-108.
191. Wensky AK, Furtado GC, Marcondes MC, Chen S, Manfra D, Lira SA, Zagzag D, Lafaille JJ. 2005. IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J Immunol 174(3):1416-1423.
192. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. 1996. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligoden-drocyte glycoprotein-induced autoimmune encephalomyeli-tis. J Immunol 157(8):3223-3227.
193. Willenborg DO, Fordham SA, Staykova MA, Ramshaw IA, Cowden WB. 1999. IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J Immunol 163(10):5278-5286.
194. Yamada T, Yamanaka I. 1995. Microglial localization of alphainterferon receptor in human brain tissues. Neurosci Lett 189(2):73-76.
195. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale M Jr., Akira S, Yonehara S, Kato A, Fujita T. 2005. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175(5): 2851-2858.
196. Yordy B, Iijima N, Huttner A, Leib D, Iwasaki A. 2012. A neuron-specific role for autophagy in antiviral defense against herpes simplex virus. Cell Host Microbe 12(3):334-345.
197. Zalckvar E, Berissi H, Mizrachy L, Idelchuk Y, Koren I, Eisenstein M, Sabanay H, Pinkas-Kramarski R, Kimchi A. 2009. DAP-kinase-mediated phosphorylation on the BH3 domain of beclin 1 promotes dissociation of beclin 1 from Bcl-X(L) and induction of autophagy. EMBO Rep 10(3):285-292.
198. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81(14):7749-7758.